Skip to main content
SpringerLink
Log in
Book cover

Surgical Oncology pp 149–169Cite as

Thyroid carcinoma

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 90))

Abstract

The surgical technique of thyroidectomy has not changed significantly since Kocher performed his first procedure for benign goiter in 1872. Since that time, however, considerable advances have been made toward understanding the physiology and pathology of the thyroid gland. The past decade has witnessed an explosion in our knowledge of the molecular events involved in the development and progression of thyroid carcinoma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   389.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   499.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   689.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Franceschi S, Boyle P, Maisonneuve P, et al. The epidemiology of thyroid carcinoma. Crit Rev Oncogen 4: 25–52, 1993.

    CAS  Google Scholar 

  2. Ron E, Modan B, Preston D, Alfandary E, Stovall M, Boice JD, Jr. Thyroid neoplasia following low-dose radiation in childhood. Radiat Res 120: 516–531, 1989.

    Article  PubMed  CAS  Google Scholar 

  3. Cady B, Sedgwick CE, Meissner WA, Wool MS, Salzman FA, Werber J. Risk factor analysis in differentiated thyroid cancer. Cancer 43: 810–819, 1979.

    Article  PubMed  CAS  Google Scholar 

  4. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102: 1088–1095, 1987.

    PubMed  CAS  Google Scholar 

  5. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in well differentiated carcinoma of the thyroid gland. Am J Surg 164: 658–661, 1992.

    Article  PubMed  CAS  Google Scholar 

  6. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am J Surg 160: 344–347, 1990.

    Article  PubMed  CAS  Google Scholar 

  7. Ruiz do Almodovar JM, Ruiz-Garcia J, Olea N, Villalobos M, Pedraza V. Analysis of risk of death from differentiated thyroid cancer. Radiother Oncol 31: 207–212, 1994.

    Article  Google Scholar 

  8. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 116: 1036–1040, 1994.

    PubMed  CAS  Google Scholar 

  9. Roque L, Castedo S, Clode A, Soares J. Deletion of 3p25 pter in a primary follicular thyroid carcinoma and its metastasis. Genes Chromosom Cancer 8: 199–203, 1993.

    Article  PubMed  CAS  Google Scholar 

  10. Antonini P, Levy N, Caillou B, et al. Numerical aberrations, including trisomy 22 as the sole anomaly, are recurrent in follicular thyroid adenomas. Genes Chromosom Cancer 8: 63–66, 1993.

    Article  PubMed  CAS  Google Scholar 

  11. Dal Cin P, Sneyers W, Sayed Aly M, et al. Involvement of 19ql3 in follicular thyroid adenoma. Cancer Genet Cytogenet 60: 99–101, 1992.

    Article  Google Scholar 

  12. Matsuo K, Tang S-H, Fagin JA. Allelotype of human thyroid tumors: Loss of chromosome 11q13 sequences in follicular neoplasms. Mol Endocrinol 5: 1873–1879, 1991.

    Article  PubMed  CAS  Google Scholar 

  13. Roque L, Castedo S, Gomes P, Soaraes P, Clode A, Soares J. Cytogenetic findings in 18 follicular thyroid adenomas. Cancer Genet Cytogenet 67: 1–6, 1993.

    Article  PubMed  CAS  Google Scholar 

  14. Antonini P, Venuat A-M, Caillou B, et al. Cytogenetic studies on 19 papillary carcinomas. Genes Chromosom Cancer 5: 206–211, 1992.

    Article  PubMed  CAS  Google Scholar 

  15. Sozzi G, Bongarzone I, Miozzo M, et al. Cytogenetic and molecular genetic characterization of papillary thyroid carcinomas. Genes Chromosom Cancer 5: 212–218, 1992.

    Article  PubMed  CAS  Google Scholar 

  16. Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thryoid carcinomas. Cancer Res 54: 2979–2985, 1994.

    PubMed  CAS  Google Scholar 

  17. Pierotti MA, Santoro M, Jenkins RB, et al. Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and ret and creating the oncogenic sequence ret/ptc. Proc Natl Acad Sci USA 89: 1616–1620, 1992.

    Article  PubMed  CAS  Google Scholar 

  18. Sozzi G, Bongarzone I, Miozzo M, et al. A t(10;17) translocation creates the ret/ptc2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosom Cancer 9: 244–250, 1994.

    Article  PubMed  CAS  Google Scholar 

  19. Minoletti F, Butti MG, Coronelli S, et al. The two genes generating RET/PTC3 are localized in chromosomal band 10qll.2. Genes Chromosom Cancer 11: 51–57, 1994.

    Article  PubMed  CAS  Google Scholar 

  20. Dobashi Y, Sugimura H, Sakamoto A, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 17: 375–381, 1993.

    Article  PubMed  CAS  Google Scholar 

  21. Dobashi Y, Sugimura H, Sakamoto A, et al. Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn Mol Pathol 3: 9–14, 1994.

    Article  PubMed  CAS  Google Scholar 

  22. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369–1371, 1992.

    PubMed  CAS  Google Scholar 

  23. Nakamura T, Yana I, Kobayashi T, et al. p53 gene mutation associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83: 1293–1298, 1992.

    Article  PubMed  CAS  Google Scholar 

  24. Donghi R, Longoni A, Pilotti S, Michieli P, Delia Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91: 1753–1760, 1993.

    Article  PubMed  CAS  Google Scholar 

  25. Zou M, Shi Y, Farid NR. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 77: 1054–1058, 1993.

    Article  PubMed  CAS  Google Scholar 

  26. Ewen ME. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev 13: 45–66, 1994.

    Article  PubMed  CAS  Google Scholar 

  27. Farid NR, Shi Y, Zou M. Molecular basis of thyroid cancer. Endocr Rev 15: 202–232, 1994.

    PubMed  CAS  Google Scholar 

  28. Khosravi-Far R, Der CJ. The ras signal transduction pathway. Cancer Metastasis Rev 13: 67–89, 1994.

    Article  PubMed  CAS  Google Scholar 

  29. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 116: 1010–1016, 1994.

    PubMed  CAS  Google Scholar 

  30. Shi YF, Zou MJ, Schmidt H, et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 51: 2690–2693, 1991.

    PubMed  CAS  Google Scholar 

  31. Karga H, Lee JK, Vickery AL, Jr., Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73: 415–418, 1991.

    Article  Google Scholar 

  32. Goretzki PE, Lyons J, Stacy-Phipps S, et al. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 16: 576–582, 1992.

    Article  PubMed  CAS  Google Scholar 

  33. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4: 1474–1479, 1990.

    Article  PubMed  CAS  Google Scholar 

  34. Wright PA, Williams ED, Lemoine DR, Wynford-Thomas D. Radiation-associated and’ spontaneous’ human thyroid carcinomas show a different pattern of ras oncogene mutation. Oncogene 6: 47173, 1991.

    Google Scholar 

  35. Di Renzo MF, Olivero M, Fero S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7: 2549–2553, 1992.

    Google Scholar 

  36. Jhiang SM, Caruso DR, Gilmore E, et al. Detection of the PTC/ret TPC oncogene in human thyroid cancer. Oncogene 7: 1331–1337, 1992.

    PubMed  CAS  Google Scholar 

  37. Mizukami Y, Nonomura A, Hashimoto T, et al. Immunohistochemical demonstration of epidermal growth factor and c-myc oncogene product in normal benign and malignant thyroid tissues. Histopathology 18: 11–18, 1991.

    Article  PubMed  CAS  Google Scholar 

  38. Assland A. Expression of oncogenes in thyroid tumors: Coexpression of c-erbB2/neu and c-erbB. Br J Cancer 57: 358–363, 1988.

    Article  Google Scholar 

  39. Di Carlo A, Mariano A, Pisano G, Parmeggiani V, Beguinot L, Macchia V. Epidermal growth factor receptor and thyrotropin response in human tissue. J Endocrinol Invest 13: 293–299, 1990.

    PubMed  Google Scholar 

  40. Shimizu T, Usuda N, Yamanda T, Sujenoya A, Iida F. Proliferative activity of human thyroid tumors evaluated by proliferative cell nuclear antigen/cyclin immunhistochemical studies. Cancer 71: 2807–2812, 1993.

    Article  PubMed  CAS  Google Scholar 

  41. Soares P, Sobrinho-Simões M. Proliferative activity of human thyroid tumors evaluated by proliferating cell nuclear antigen/cyclin immunhistochemical studies. Cancer 73: 2880–2881, 1994.

    Article  Google Scholar 

  42. Tateyama H, Yang Y-P, Eimoto T, et al. Proliferative cell nuclear antigen expression in follicular tumours of the thyroid with special reference to oxyphilic cell lesions. Virchows Arch 424: 533–537, 1994.

    Article  PubMed  CAS  Google Scholar 

  43. Piromalli D, Martelli G, Del Prato I, Collini P, Pilotti S. The role of fine-needle aspiration in diagnosis of thyroid nodules: Analysis of 795 consecutive cases. J Surg Oncol 50: 247–250, 1992.

    Article  PubMed  CAS  Google Scholar 

  44. Caraway NP, Sneige N, Samaan NA. Diagnostic pitfalls in thyroid fine-needle aspiration: A review of 394 cases. Diagn Cytopathol 9: 345–350, 1993.

    Article  PubMed  CAS  Google Scholar 

  45. Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB. Indeterminate fine-needle aspiration biopsy of the thyroid: Identification of subgroups at high risk for invasive carcinoma. Surgery 116: 1054–1160, 1994.

    PubMed  CAS  Google Scholar 

  46. DeMicco C, Vasko V, Garcia S, Zoro P, Denizot A, Henry JF. Fine-needle aspiration of thyroid follicular neoplasm: Diagnostic use of thyroid peroxidase immunocytochemistry with monoconal antibody Surgery 116: 1031–1035, 1994.

    CAS  Google Scholar 

  47. Russell P, Lean CL, Delbridge L, May GL, Dowd S, Mountford CE. Proton magnetic resonance and hyman thyroid neoplasia 1: Discrimination between benign and malignant neoplasms. Am J Med 96: 383–388, 1994.

    Article  PubMed  CAS  Google Scholar 

  48. Van Sorge-Van Boxtel RAJ, Van Eck-Smit BLF, Goslings BM. Comparison of serum thyrogobulin, l311 and 201TI scintigraphy in the postoperative follow-up of differentiated thyroid cancer. Nucl Med Commun 14: 365–372, 1993.

    Article  Google Scholar 

  49. Ramanna L, Waxaman A, Braunstein G. Thallium-210 scintigraphy in differentiated thyroid cancer: Comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med 32: 441–446, 1991.

    PubMed  CAS  Google Scholar 

  50. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy. J Clin Endocrinol Metab 77: 1090–1094, 1993.

    Article  PubMed  CAS  Google Scholar 

  51. DeJong SA, Demeter JG, Lawrence AN, Palowan E. Necessity and safety of completion thyroidectomy for differentiated thyroid carcinoma. Surgery 112: 734–739, 1992.

    CAS  Google Scholar 

  52. Pasieka JL, Thompson NW, McLeod MK, Burney RE, Macha M. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 16: 711–717, 1992.

    Article  PubMed  CAS  Google Scholar 

  53. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418–428, 1994.

    Article  PubMed  CAS  Google Scholar 

  54. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well-differentiated thyroid carcinoma: A retrospective review of 1599 patients. J Clin Endocrinol Metab 75: 714–720, 1992.

    Article  PubMed  CAS  Google Scholar 

  55. Friedman M, Danielzadeh JA, Caldarelli DD. Treatment of patients with carcinoma of the thyroid invading the airway. Arch Otolaryngol Head Neck Surg 120: 1377–1381, 1994.

    Article  PubMed  CAS  Google Scholar 

  56. McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck 16: 165–172, 1994.

    Article  PubMed  CAS  Google Scholar 

  57. O’Connell MEA, A’Hern RP, Harmer CL, et al. Results of external beam radiotherapy indifferentiated thyroid carcinoma: A respective study from the Royal Marsden Hospital. Eur J Cancer 30A: 733–739, 1994.

    Article  PubMed  Google Scholar 

  58. Ang KK, Kaanders JHAM, Peters LJ. Radiotherapy for head and neck cancers: Indications & techniques. Malvern, PA: Lea & Febiger, 1994, p 119.

    Google Scholar 

  59. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid — A clinicopathologic entity. J Clin Endocrinol Metab 19: 152–161, 1959.

    Article  PubMed  CAS  Google Scholar 

  60. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. Am J Med 31: 163–166,1961.

    Article  Google Scholar 

  61. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism, and Cushing’s disease: Multiple endocrine neoplasia, Type II. Medicine 47: 371–409, 1968.

    Article  PubMed  CAS  Google Scholar 

  62. Mulligan LM, Kwok LBJ, Healey CS, et al. Germ-line mutations of the RET proto-oncogene and multiple endocrine neoplasia type IIA. Nature 363: 45860, 1993.

    Article  Google Scholar 

  63. Donis-Keller H, Dou S, GC HID, et al. Mutations in the RET proto-oncogene are associated with MEN IIA and FMTC. Hum Mol Genet 851–856, 1993.

    Google Scholar 

  64. Feldman GL, Kambouris M, Talpos GB, Mulligan LM, Ponder BAJ, Jackson CE. Clinical value of direct DNA analysis of the RET proto-oncogene in families with multiple endocrine neoplasia type IIA. Surgery 116: 1042–1047, 1994.

    PubMed  CAS  Google Scholar 

  65. Schröder S, Schwarz W, Rehpenning W, Dralle H, Bay V, Böcker W. Leu-M1 immunoreac-tivity and prognosis in medullary carcinomas of the thyroid gland. J Cancer Res Clin Oncol 114: 291–296, 1988.

    Article  PubMed  Google Scholar 

  66. Pyke CM, Hay ID, Goellner JR, Bergstralh EJ, van Heerden JA, Grant CS. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery 110: 964–971, 1991.

    PubMed  CAS  Google Scholar 

  67. Ekman ET, Bergholm U, Bäckdahl M, et al. and the Swedish Medullary Thyroid Study Group. Nuclear DNA content and survival in medullary thyroid carcinoma. Cancer 65: 511–517, 1990.

    Article  PubMed  CAS  Google Scholar 

  68. Wells S, Baylin S, Leight G, Dale JK, Dilley WG, Farndon JR. The importance of early diagnosis in patients with heritary medullary thyroid carcinoma. Ann Surg 195: 595, 1982.

    Article  PubMed  Google Scholar 

  69. Wells SA Jr., Haagensen DE, Linehan WM, Farrell RE, Dilley WG. The detection of elevated plasmal levels of carcinocmbryonic antigen in patients with suspected or established medullary thyroid carcinoma. Cancer 42: 1498–1503, 1978.

    Article  PubMed  CAS  Google Scholar 

  70. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl-2 immunoreactivity in medullary thyroid carcinoma. Hum Pathol 26: 945–950, 1995.

    Article  PubMed  CAS  Google Scholar 

  71. Roncalli M, Viale G, Grimelius L, et al. Prognostic value of N-MYC immunoreactivity in medullary thyroid carcinoma. Cancer 74: 134–141, 1994.

    Article  PubMed  CAS  Google Scholar 

  72. Skopelitou A, Korkolopoulou P, Papanikolaou A, Hadjiyannakis M. Proliferating cell nuclear antigen (PCNA) in medullary thyroid carcinoma. J Cancer Res Clin Oncol 119: 379–381, 1993.

    Article  PubMed  CAS  Google Scholar 

  73. Längle F, Soliman T, Neuhold N, etal. Study Group on Multiple Endocrine Neoplasia of Austria. CD15 (LeuM1) immunoreactivity: Prognostic factor for sporadic and hereditary medullary thyroid cancer? World J Surg 18: 583–587, 1994.

    Article  PubMed  Google Scholar 

  74. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: Prognosis familial versus sporadic disease in the role of radiotherapy. J Clin Endocrinol Metab 67: 801–805, 1988.

    Article  PubMed  CAS  Google Scholar 

  75. Sarrazin D, Fontaine F, Rougier P, et al. Role of radiotherapy in the treatment of medullary cancer of the thyroid. Bull Cancer 71: 200–208, 1984.

    PubMed  CAS  Google Scholar 

  76. Nguyen TD, Chassard JL, Lagarde P, et al. Results of postoperative radiation therapy in medullary carcinoma of the thyroid: A retrospective study by the French Federation of Cancer Institutes — The Radiotherapy Cooperative Group. Radiother Oncol 23: 1–5, 1992.

    Article  PubMed  CAS  Google Scholar 

  77. Wu L-T, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire III WP. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73: 432–435, 1994.

    Article  PubMed  CAS  Google Scholar 

  78. Orlandi F, Caraci P, Berruti A, et al. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 5: 763–765, 1994.

    PubMed  CAS  Google Scholar 

  79. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE, and the Groupe d’Etude des Tumeurs á Calcitonine (GETC). Treatment of advanced medullary thyroid cancer with an alternating combination of 5FU-streptozocin and 5-FU-dacarbazine. Br J Cancer 71: 363–365, 1995.

    Article  PubMed  CAS  Google Scholar 

  80. Rougier P, Calmettes C, Laplanche A, et al. The values of calcitonin and carcinoembryonic antigen in the treatment and management of non-familial medullary thyroid carcinoma. Cancer 51: 885–962, 1983.

    Article  Google Scholar 

  81. Saad MF, Fritsche HA, Jr., Samaan NA. Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 58: 889–894, 1984.

    Article  PubMed  CAS  Google Scholar 

  82. Johnson DG, Coleman RE, McCook TA, Dale JK, Wells SA. Bone and liver images in medullary carcinoma of the thyroid gland: Concise communication. J NucI Med 25: 419–422, 1984.

    CAS  Google Scholar 

  83. Abdelmoumene N, Schlumberger M, Gardet P, et al. Selective venous sampling catheterization for localisation of persisting medullary thyroid carcinoma. Br J Cancer 69: 1141–1144, 1994.

    Article  PubMed  CAS  Google Scholar 

  84. Waddington WA, Kettle AG, Heddle RM, Coakley AJ. Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 21: 363–364, 1994.

    Article  PubMed  CAS  Google Scholar 

  85. Juweid M, Sharkey RM, Behr T, et al. Targeting and initial radio-immunotherapy of medullary thyroid carcinoma with 1311-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 55(Suppl M): 5946s–5951s, 1995.

    PubMed  CAS  Google Scholar 

  86. Tisell LE, Hansson G, Jansson S, Salander H. Re-operation in the treatment of asymptomatic metastizing medullary thyroid carcinoma. Surgery 99: 60–66, 1986.

    PubMed  CAS  Google Scholar 

  87. Buhr HJ, Kallinowski F, Raue F, Frank-Raue K, Herfarth C. Microsurgical neck dissection for metastisizing medullary thyroid carcinoma. Eur J Surg Oncol 21: 195–197, 1995.

    Article  PubMed  CAS  Google Scholar 

  88. Van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent currative primary surgery for medullary thyroid carcinoma. Ann Surg 212: 395–401, 1990.

    Article  Google Scholar 

  89. Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 18: 83–88, 1992.

    PubMed  CAS  Google Scholar 

  90. Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: Risk factors and outcome. Surgery 110: 956–963, 1991.

    PubMed  CAS  Google Scholar 

  91. Tan RK, Finley RK III, Driscoll D, Bakamjian V, Hicks WL, Shedd DP. Anaplastic carcinoma of the thyroid: A 24-year experience. Head Neck 17: 41–48, 1995.

    Article  PubMed  CAS  Google Scholar 

  92. Venkatesh YSS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NG. Anaplastic carcinoma of the thyroid. A clinical pathologic study of 1 to 1 cases. Cancer 66: 321–330, 1990.

    Article  PubMed  CAS  Google Scholar 

  93. Schlumberger M, Parmentier C, Delisle M-J, Couette J-E, Droz J-P, Sarrazin D. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67: 564–566, 1991.

    Article  PubMed  CAS  Google Scholar 

  94. Tennvall J, Lundell G, Hallquist A, Wahlberg P, Wallin G, Tibblin S and the Swedish Anaplastic Thyroid Cancer Group. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Cancer 74: 1348–1354, 1994.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ann M. Gillenwater
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Randal S. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, The University of Texas, Houston, Texas, USA

    Raphael E Pollock M.D., Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gillenwater, A.M., Weber, R.S. (1997). Thyroid carcinoma. In: Pollock, R.E. (eds) Surgical Oncology. Cancer Treatment and Research, vol 90. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6165-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6165-1_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7826-6

  • Online ISBN: 978-1-4615-6165-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation